NSGO-CTU/HERO
Characterization of High-Grade Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype – A Prospective Observational Study
NSGO-CTU
ENGOT-ov56-NSGO-CTU/DOVACC
A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients with Recurrent Ovarian Cancer
Trial Number
NCT04742075 (ClinicalTrials.gov Identifier)Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number
GCIG SB-001/NSGO-CTU-PEACE
Studying the feasibility of collecting data on patient/carer satisfaction with end of life (EOL) care and of collecting details of that care in women with advanced gynaecological malignancies.
Trial Number
NCT05142150 (ClinicalTrials.gov Identifier)Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number
ENGOT-OV30 / NSGO - UMBRELLA
A phase II umbrella trial in patients with relapsed ovarian cancer.
Trial Number
NCT03267589 (ClinicalTrials.gov Identifier)Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number
ENGOT-OV24 / NSGO-AVANOVA2
Niraparib and niraparib-bevacizumab combination against bevacizumab alone in Women with Homologous Recombination Deficient (HRD) platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.
Trial Number
NCT02354131 (ClinicalTrials.gov Identifier)Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number
ENGOT-OV24 / NSGO-AVANOVA1
Niraparib and niraparib-bevacizumab combination against bevacizumab alone in Women with Homologous Recombination Deficient (HRD) platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.
Trial Number
NCT02354131 (ClinicalTrials.gov Identifier)Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number
ENGOT-EN3 / NSGO - PALEO
Trial of Letrozole +/- Palbociclib in Metastatic Endometrial Cancer
Trial Number
NCT02730429 (ClinicalTrials.gov Identifier)Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number
ENGOT-EN1 / NSGO- FANDANGO
ENGOT-EN1/FANDANGO: A Randomized Phase II Trial of First-line Combination Chemotherapy With Nintedanib / Placebo for Patients With Advanced or Recurrent Endometrial Cancer
Trial Number
NCT02730416 (ClinicalTrials.gov Identifier)Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number
ENGOT-EN2 / DGCG
A phase II Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer.